WILMINGTON, DE / ACCESSWIRE / October 7, 2020 / Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ:EIDX) ("Eidos" or the "Company") relating to the sale of the Company to BridgeBio Pharma, Inc. ("BridgeBio"), which owns and controls over 63% of Eidos. The two parties have announced that they reached an agreement in principle pursuant to which BridgeBio will acquire Eidos. As a result of the merger, Eidos shareholders are only anticipated to receive either 1.85 shares of BridgeBio common stock or $73.26 per share in cash in exchange for each share of Eidos.
Andrews & Springer's investigation so far has revealed that the consideration Eidos shareholders are expected to receive is inadequate. Our Firm's investigation so far has discovered that the process leading up to the announcement of the merger appears to have significant conflicts of interest, thus making the process and consideration unfair. Andrews & Springer is also investigating whether the Eidos directors breached their fiduciary duties by failing to adequately shop the company and maximize shareholder value.
If you own shares of Eidos and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/eidos-merger-class-action-investigation/ or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn - www.linkedin.com/company/andrews-&-springer-llc, Twitter - www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq.
Toll Free: 1-800-423-6013
SOURCE: Andrews & Springer LLC